Waldemar Debinski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Waldemar Debinski has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Denise M. Gibo
Section of Neurosurgery/H110, Department of Surgery, Pennsylvania State University College of Medicine, Hershey, USA
3 shared publicationsRaj K. Puri
Laboratory of Molecular Tumor Biology, Food and Drug Administration, Bethesda, MD, USA
2 shared publicationsAynsley Kealiher
1 shared publicationD M Gibo
1 shared publicationG Y Gillespie
1 shared publicationJ P Thompson
1 shared publication
Latest Publications
- Open Access
- 1 May 2000
- Published by Springer Nature in Molecular Medicine
- Vol. 6 (5) , 440-449
Molecular Expression Analysis of Restrictive Receptor for Interleukin 13, a Brain Tumor-associated Cancer/Testis Antigen
The vast majority of patients with high-grade gliomas (HGG) over-express interleukin 4 (IL4)-independent binding sites for IL13 in situ. In addition, mutated IL13-based cytotoxins directed specifically toward glioma-associated sites are arguably the most active anti-glioma agents. Two IL13 receptor (R) proteins were identified: (1) IL13Ra′, a component of the signaling, het-erodimeric high-affinity receptor for IL13 that is shared with IL4, and (2) IL13Rα, a monomeric, IL4-independent receptor. We analyzed gene expression of IL13Rα, IL13Rα′ and that of IL4Rβ, which is the other subunit of the shared ILl3/4 receptor. The study was conducted with 40 human normal adult tissues, 20 discrete regions of the central nervous system (CNS), 7 fetal tissues, several cultured cell lines, and surgical CNS specimens. The most striking feature of the IL13Rα gene expression was the virtual lack of its transcripts within the CNS. Furthermore, only the testes exhibited a prominent presence of the mRNA for IL13Rα among peripheral organs. In contrast, the components of the shared ILl3/4 receptor were readily detected both in the CNS and in vital organs, such as liver, heart, lungs, and gastrointestinal tract. The results strongly support a need to redirect IL13 towards its more restrictive, IL4-independent, receptor for glioma diagnosis and therapies. Moreover, the gene for IL13Rα resides on chromosome X. Since IL13Rα is (1) a cancer-associated protein, (2) virtually restricted to testes among normal tissues, and (3) its gene is on chromosome X, IL13Rα is unexpectedly categorized as a cancer/testis antigen. Our findings make IL13Rα even more attractive as a target for variety of approaches in glioma molecular management.
- 1 May 2000
- Published by Springer Nature in Molecular Medicine
- Vol. 6 (5) , 440-449
Open AccessMolecular Expression Analysis of Restrictive Receptor for Interleukin 13, a Brain Tumor-associated Cancer/Testis Antigen
The vast majority of patients with high-grade gliomas (HGG) over-express interleukin 4 (IL4)-independent binding sites for IL13 in situ. In addition, mutated IL13-based cytotoxins directed specifically toward glioma-associated sites are arguably the most active anti-glioma agents. Two IL13 receptor (R) proteins were identified: (1) IL13Ra′, a component of the signaling, het-erodimeric high-affinity receptor for IL13 that is shared with IL4, and (2) IL13Rα, a monomeric, IL4-independent receptor. We analyzed gene expression of IL13Rα, IL13Rα′ and that of IL4Rβ, which is the other subunit of the shared ILl3/4 receptor. The study was conducted with 40 human normal adult tissues, 20 discrete regions of the central nervous system (CNS), 7 fetal tissues, several cultured cell lines, and surgical CNS specimens. The most striking feature of the IL13Rα gene expression was the virtual lack of its transcripts within the CNS. Furthermore, only the testes exhibited a prominent presence of the mRNA for IL13Rα among peripheral organs. In contrast, the components of the shared ILl3/4 receptor were readily detected both in the CNS and in vital organs, such as liver, heart, lungs, and gastrointestinal tract. The results strongly support a need to redirect IL13 towards its more restrictive, IL4-independent, receptor for glioma diagnosis and therapies. Moreover, the gene for IL13Rα resides on chromosome X. Since IL13Rα is (1) a cancer-associated protein, (2) virtually restricted to testes among normal tissues, and (3) its gene is on chromosome X, IL13Rα is unexpectedly categorized as a cancer/testis antigen. Our findings make IL13Rα even more attractive as a target for variety of approaches in glioma molecular management.
- 1 December 1999
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 886 (1) , 297-299
Recombinant Cytotoxins Specific for Cancer Cells
- 1 December 1999
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 886 (1) , 297-299
Recombinant Cytotoxins Specific for Cancer Cells
- 1 October 1999
- Vol. 5, 3143s-3147s
Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas.
A vast majority of patients with glioblastoma multiforme (GBM), a high-grade glioma, overexpress abundant amounts of a receptor for interleukin (IL)-13 in situ. This receptor is more restrictive because it is IL-4-independent and therefore differs from the IL-13/4 signaling receptor of normal tissue that is shared with IL-4. We previously identified one of the sites on the human IL (hIL)-13 molecule that is important for its interaction with the IL-13/4 receptor, a residue of glutamic acid at position 13. In this study, we mutated the cytokine and produced hIL-13.E13Y, in which the glutamic acid was substituted by tyrosine. This additional tyrosine residue was therefore strategically located within the region of IL-13 interaction with the signaling physiological receptor. hIL-13.E13Y did not transduce signals through the IL-13/4 receptor, whereas its interaction with the more restrictive, GBM-associated receptor remained intact. The mutated hIL-13 could be readily radiolabeled. Radiolabeled hIL-13.E13Y produced specific autoradiographic images of human GBM specimens. We demonstrate an effective way to redirect hIL-13 to its more restrictive receptor found in high-grade gliomas by mutagenizing the cytokine, and, concomitantly, we equipped hIL-13 with an additional tyrosine residue for higher specific activity radiolabeling.
- 1 October 1999
- Vol. 5, 3143s-3147s
Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas.
A vast majority of patients with glioblastoma multiforme (GBM), a high-grade glioma, overexpress abundant amounts of a receptor for interleukin (IL)-13 in situ. This receptor is more restrictive because it is IL-4-independent and therefore differs from the IL-13/4 signaling receptor of normal tissue that is shared with IL-4. We previously identified one of the sites on the human IL (hIL)-13 molecule that is important for its interaction with the IL-13/4 receptor, a residue of glutamic acid at position 13. In this study, we mutated the cytokine and produced hIL-13.E13Y, in which the glutamic acid was substituted by tyrosine. This additional tyrosine residue was therefore strategically located within the region of IL-13 interaction with the signaling physiological receptor. hIL-13.E13Y did not transduce signals through the IL-13/4 receptor, whereas its interaction with the more restrictive, GBM-associated receptor remained intact. The mutated hIL-13 could be readily radiolabeled. Radiolabeled hIL-13.E13Y produced specific autoradiographic images of human GBM specimens. We demonstrate an effective way to redirect hIL-13 to its more restrictive receptor found in high-grade gliomas by mutagenizing the cytokine, and, concomitantly, we equipped hIL-13 with an additional tyrosine residue for higher specific activity radiolabeling.
- 1 May 1999
- Vol. 5 (5) , 985-90
Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.
Glioblastoma multiforme (GBM) is an incurable brain tumor. Due to the striking heterogeneity that characterizes GBM, there is no known tumor-specific antigen or receptor that is expressed by a majority of GBM patients. We found that virtually all studied human GBM specimens (23 samples) abundantly expressed a receptor for interleukin (IL)-13 in situ, whereas normal human brain had few, if any, IL-13-binding sites. The GBM-associated IL-13 receptor was both quantitatively and qualitatively different from and, thus, more restrictive than the shared signaling receptor of normal tissue: it was IL-4 independent. The receptor for IL-13 was overexpressed by a majority of cancer cells in situ. Furthermore, cytotoxins targeted to this more restrictive IL-13R produced cures in animals bearing xenografts of human high-grade gliomas. Thus, unexpectedly, the receptor for an immune regulatory cytokine may be a long sought marker and, concomitantly, a unique imaging site and therapeutic target for GBM, the most malignant and the most heterogeneous of brain tumors.
- 1 May 1999
- Vol. 5 (5) , 985-90
Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.
Glioblastoma multiforme (GBM) is an incurable brain tumor. Due to the striking heterogeneity that characterizes GBM, there is no known tumor-specific antigen or receptor that is expressed by a majority of GBM patients. We found that virtually all studied human GBM specimens (23 samples) abundantly expressed a receptor for interleukin (IL)-13 in situ, whereas normal human brain had few, if any, IL-13-binding sites. The GBM-associated IL-13 receptor was both quantitatively and qualitatively different from and, thus, more restrictive than the shared signaling receptor of normal tissue: it was IL-4 independent. The receptor for IL-13 was overexpressed by a majority of cancer cells in situ. Furthermore, cytotoxins targeted to this more restrictive IL-13R produced cures in animals bearing xenografts of human high-grade gliomas. Thus, unexpectedly, the receptor for an immune regulatory cytokine may be a long sought marker and, concomitantly, a unique imaging site and therapeutic target for GBM, the most malignant and the most heterogeneous of brain tumors.
- Open Access
- 18 May 1998
- Published by Wiley in International Journal of Cancer
- Vol. 76 (4) , 547-551
Novel way to increase targeting specificity to a human glioblastoma-associated receptor for interleukin 13
Human brain cancers (gliomas) overexpress large numbers of a receptor for interleukin 13 (IL13), making this receptor an attractive target for anti‐glioma therapies. We have recently proposed that the glioma‐associated IL13 receptor is different from the one expressed on some hemopoietic and somatic cells. In an attempt to identify an even more glioma‐specific target, we have used an antagonist of a related cytokine, IL4, which neutralizes the physiological effects of both IL13 and IL4 on normal cells. Here we demonstrate that the IL4 antagonist also counteracts the action of cytotoxins targeted to the IL13 receptor on normal human cells. Importantly, the IL4 antagonist does not inhibit IL13‐based cytotoxins on glioma cells at all. Thus, the IL13 receptor on glioma cells can be categorized as tumor‐specific in the presence of an IL4 antagonist. We conclude that IL13 receptor‐directed cytotoxins can be delivered to glioma cells without being cytotoxic to normal cells. Int. J. Cancer 76:547–551, 1998.
- 18 May 1998
- Published by Wiley in International Journal of Cancer
- Vol. 76 (4) , 547-551
Open AccessNovel way to increase targeting specificity to a human glioblastoma-associated receptor for interleukin 13
Human brain cancers (gliomas) overexpress large numbers of a receptor for interleukin 13 (IL13), making this receptor an attractive target for anti‐glioma therapies. We have recently proposed that the glioma‐associated IL13 receptor is different from the one expressed on some hemopoietic and somatic cells. In an attempt to identify an even more glioma‐specific target, we have used an antagonist of a related cytokine, IL4, which neutralizes the physiological effects of both IL13 and IL4 on normal cells. Here we demonstrate that the IL4 antagonist also counteracts the action of cytotoxins targeted to the IL13 receptor on normal human cells. Importantly, the IL4 antagonist does not inhibit IL13‐based cytotoxins on glioma cells at all. Thus, the IL13 receptor on glioma cells can be categorized as tumor‐specific in the presence of an IL4 antagonist. We conclude that IL13 receptor‐directed cytotoxins can be delivered to glioma cells without being cytotoxic to normal cells. Int. J. Cancer 76:547–551, 1998.
- 1 May 1998
- Published by Springer Nature in Nature Biotechnology
- Vol. 16 (5) , 449-453
Novel anti–brain tumor cytotoxins specific for cancer cells
The vast majority of brain cancers (gliomas) express a receptor (R) for interleukin 13 (IL13). In order to achieve specific targeting of the IL13R in gliomas, we have mutagenized human (h) IL13. The mutation was made to alter IL13 interaction with the shared functional IL13/4 normal tissue receptor, but not with the glioma-associated receptor. We have thus produced hIL13.E13K (glutamic acid at position 13 changed to lysine) and fused it to derivatives of Pseudomonas exotoxin A. The hIL13.E13K-based cytotoxins are less active on normal cells and thus less toxic, and are better antitumor agents compared with the cytotoxins containing nonmutagenized hIL13.
- 1 May 1998
- Published by Springer Nature in Nature Biotechnology
- Vol. 16 (5) , 449-453
Novel anti–brain tumor cytotoxins specific for cancer cells
The vast majority of brain cancers (gliomas) express a receptor (R) for interleukin 13 (IL13). In order to achieve specific targeting of the IL13R in gliomas, we have mutagenized human (h) IL13. The mutation was made to alter IL13 interaction with the shared functional IL13/4 normal tissue receptor, but not with the glioma-associated receptor. We have thus produced hIL13.E13K (glutamic acid at position 13 changed to lysine) and fused it to derivatives of Pseudomonas exotoxin A. The hIL13.E13K-based cytotoxins are less active on normal cells and thus less toxic, and are better antitumor agents compared with the cytotoxins containing nonmutagenized hIL13.